• linkedin
  • Increase Font
  • Sharebar

    Cyclosporine A found efficacious for refractory IC

    Small study shows treatment associated with improvements in symptoms, QoL at 5 years

     

    Agent well tolerated

    Daher Chade, MDDr. ChadeDr. Chade, who presented the findings at the 2014 AUA annual meeting in Orlando, FL, said all the patients had been previously unsuccessfully treated with at least two other drugs. The study showed all 45 patients had an ICPI score above 8 before treatment, but only 22% of the patients remained in that group after treatment with cyclosporine A. The agent was found to be well tolerated, and no significant abnormalities were found for liver and renal function.

    “The most common side effects were mild dyspepsia, diarrhea, and hair growth. The significant adverse events that led to dose reduction or interruption of treatment were hypertension and gingival hyperplasia (9/45 patients),” Dr. Chade said.

    Study patients had a mean ICSI score of 36 at baseline, but it decreased to 21.6 at 6 months. At 5 years of treatment, that number dropped even further to 8.4. Dr. Chade said the study demonstrated that the mean initial filling sensation increased from 103 mL from baseline to 170 mL after 5 years of treatment.

    “Although the etiology of interstitial cystitis is widely unknown, it seems that an autoimmune mechanism plays a significant role. Therefore, this and possibly several other immunemodulators may eventually become important alternatives for therapy in this challenging disease. I think it can be widely adopted. Some physicians are reluctant to prescribe it, but we had a good response. Our group is planning a multi-institutional trial with a larger cohort of patients with the aim of validating our findings,” Dr. Chade told Urology Times.

     

    More from Urology Times

    Has the current state of medicine affected your retirement plans?

    Coverage for OAB nerve stim device expands

    FDA approves antibacterial for complicated UTI


    Subscribe to Urology Times to get monthly news from the leading news source for urologists.
     

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results